Curriculum Vitae

Name	**Taku Kobayashi**
Country	**Japan**
Organization	**Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital**
Current Position	**Vice Director and Associate Professor**

Educational Background

1992-1998	Nagoya University School of Medicine, Nagoya, Japan (M.D.)
2004-2008	Nagoya University Graduate School of Medicine, Nagoya, Japan (Ph.D.)

Professional Experience

1998-2000	Residency in Medicine, Toyohashi Municipal Hospital, Aichi, Japan
2000-2002	Residency in Internal Medicine, Toyohashi Municipal Hospital, Aichi, Japan
2002-2004	Clinical Fellowship in Internal Medicine, KKR Tokai Hospital, Nagoya
2004-2008	Researcher in Gastroenterology, Keio University, Tokyo, Japan
2008-2009	Instructor in Gastroenterology, Keio University, Tokyo, Japan
2009-2012	Postdoctoral Research Associate, University of North Carolina at Chapel Hill, NC, USA
2012-2013	Chief Physician in Gastroenterology, Kitasato University Kitasato Institute Hospital
2013-present	Vice Director in Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital
2014-present	Associate Professor/Vice Director, Center for Advanced IBD Research and Treatment, KitasatoUniversity Kitasato Institute Hospital

Professional Organizations

American Gastroenterological Association
European Crohn's and Colitis Organization
Japanese Society of Internal Medicine
Japanese Society of Gastroenterology
Japanese Society of Gastroentorological Endoscopy
Japan Society of Coloproctology
The Japan Society of Colon Examination
Japanese Society for Inflammatory Bowel Diseases (Chairman of International Committee)
Asian Organization of Crohn's and Colitis (Clinical Research Committee)
Japanese Society for Mucosal Immunology
Japanese Gastroenterological Association

Main Scientific Publications

1. **Kobayashi T**, Uda A, Udagawa E, Hibi T. Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis. J Crohns Colitis 2019 in press
2. Sandborn WJ, Baert F, Danese S, Krznarić Z, **Kobayashi T**, et al. Efficacy and Safety of a New Vedolizumab Subcutaneous Formulation in Ulcerative Colitis: VISIBLE 1 Randomized Trial. Gastroenrterol 2019 Aug 28. pii: S0016-5085(19)41247-X. doi: 10.1053/j.gastro.2019.08.027.
3. Naganuma M, **Kobayashi T**, Nasuno M, et al. Significance of Conducting 2 Types of Fecal Tests in Patients with Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 Aug 5.
4. **Kobayashi T**, Udagawa E, Uda A, Hibi T, Hisamatsu T. Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: a claims database analysis. J Gastroenterol Hepatol. 2019 Aug 8. doi: 10.1111/jgh.14825.
5. Sagami S, **Kobayashi T**[corresponding author], Kikkawa N, et al. Combination of colonoscopy and magnetic resonance enterography is more useful forclinical decision making than colonoscopy alone in patients with complicated Crohn's disease. PLoS One 2019 Feb 20;14(2):e0212404. doi: 10.1371/journal.pone.0212404.
6. Ozaki R, **Kobayashi T**[corresponding author], Okabayashi S, et al. Histological Risk Factors to Predict Clinical Relapse in Ulcerative Colitis with Endoscopically Normal Mucosa. J Crohns Colitis. 2018 Nov 15;12(11):1288-1294
7. Ueno A, Jeffery L, **Kobayashi T**, Hibi T, Ghosh S, Jijon H. Th17 plasticity and its relevance to inflammatory bowel disease. J Autoimmun. 2018 Feb;87:38-49.
8. Matsuoka K, **Kobayashi T*** [first authorship shared], Ueno F, et al.. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol 2018 Mar;53(3):305-353
9. Naganuma M, Sugimoto S, Mitsuyama K, **Kobayashi T**, et al. Efficacy of Indigo naturalis in a Multicenter Randomized Controlled Trial of Patients with Ulcerative Colitis. Gastroenterology. 2017 Nov 22. pii: S0016-5085(17)36382-5.
10. Okabayashi, S, **Kobayashi T** [corresponding author], Nakano, M, et al. A simple 1-day colon capsule endoscopy procedure demonstrated to be a highly acceptable monitoring tool for ulcerative colitis. Inflamm Bowel Dis 2018 Oct 12;24(11):2404-2412
11. Toyonaga T, **Kobayashi T** [corresponding author], Nakano M, et al.. Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome. PLoS ONE 12(9): e0185131.
12. **Kobayashi T** [corresponding author], Hishida A, Tanaka H, et al. PhDReal-world Experience of Anti-Tumor Necrosis Factor Therapy for Internal Fistulas in Crohn's Disease: A Retrospective Multicenter Cohort Study. Inflamm Bowel Dis 2017 23(12):2245-2251
13. **Kobayashi T**, Suzuki Y, Motoya S, et al. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post-hoc analysis. J Gastroenterol 2016 Mar;51(3):241-51.
14. Yokoyama Y*, Matsuoka K*, **Kobayashi T***[*First authorship shared], et al. A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: Treatment outcomes of 847 patients in clinical practice. J Crohn Colitis 2014 May;11(5):272-3
15. Steinbach EC, **Kobayashi T**, Russo SM, et al. Innate PI3K p110δ regu lates Th1/Th17 development and microbiota-dependent colitis. J Immunol 2014 Apr 15;192(8):3958-68
16. **Kobayashi T**, Steinbach EC, Russo SM, et al. NFIL3-Deficient Mice Develop Microbiota-Dependent, IL-12/23-Driven Spontaneous Colitis. J Immunol 2014 Feb 15;192(4):1918-27